UBS Downgrades Xylem to Neutral, Lowers Price Target to $132

Benzinga Newsdesk www.benzinga.com Negative 92.5%

Neg 92.5% Neu 0% Pos 0%

UBS analyst Joshua Spector downgrades Xylem (NYSE:XYL) from Buy to Neutral and lowers the price target from $152 to $132.